UK markets closed

Prelude Therapeutics Incorporated (PRLD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
3.8800+0.0100 (+0.26%)
As of 01:16PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close3.8700
Open3.8700
Bid3.7200 x 100
Ask4.0900 x 100
Day's range3.8700 - 4.1240
52-week range1.6600 - 6.8900
Volume9,239
Avg. volume69,290
Market cap213.092M
Beta (5Y monthly)1.50
PE ratio (TTM)N/A
EPS (TTM)-2.0200
Earnings date06 May 2024 - 10 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.80
  • Simply Wall St.

    Several Insiders Invested In Prelude Therapeutics Flagging Positive News

    It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...

  • GlobeNewswire

    Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting

    Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematological models as monotherapy and provides improved depth and duration of response in combination with BTK/BCL2 inhibition Next Generation CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targe

  • GlobeNewswire

    Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting

    Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitorWILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been acc